Protocol Review Committee

Protocol Review Committee (PRC)

The NCI requires that each Cancer Center maintain a Protocol Review and Monitoring System (PRMS) to assess scientific merit and feasibility of all protocols studying subjects diagnosed with, or at risk for, cancer conducted at the Center, and to monitor for accrual and scientific relevance.  NCI looks for centralized oversight across the entire Center; the Protocol Review Committee (PRC) serves as the centralized portion of this requirement (as opposed to the Disease Site Committees).

The PRC is charged with review of the scientific rationale, study design, expected accrual rates, adequacy of biostatistical input, feasibility for completion within a reasonable time period, prioritization in terms of scientific merit and patient availability, and review of scientific progress including reasonable study goals and accrual rates.  The PRC has final authority regarding protocol and amendment review and approval, accrual monitoring, and study closure.   The UCSF IRB, the Committee on Human Research (CHR), will not grant initial approval for any cancer-related study until the PRC has granted full approval or exemption, and may hold up approval of a protocol amendment if not reviewed by the PRC prior to CHR review.

All studies reviewed by the PRC will be subject to:

  • prioritization score independent of that from the Disease Site Committee
  • required review of all protocol amendments
  • annual review for scientific relevance and accrual
  • closure due to lack of scientific relevance and/or poor accrual.

To apply:

  1. Make sure you have a disease site committee review scheduled first – see Disease Site Committee
  2. Contact to obtain a login account and training in OnCore (UCSF’s Clinical Trials Monitoring System)
  3. Follow the instructions in the PRC (ePRMS) User Manual to complete a new Submission Form using the ePRMS Submission Console in OnCore.

Helpful Links

Email with any questions.

>2017 PRC Meeting Schedule
>Site Committee Chairs and Administrators
>Protocol Review Committee roster


Forms and Policies

> see Protocol Review Committee Forms

> for Protocol Review Committee review process policies see ITR Policies


This unit is supported by a National Cancer Institute Cancer Center Support Grant (5P30CA082103). Any publications related to work done by this core should reference grant number 5P30CA082103 and must include a PMCID as required by the NIH. For complete instructions on how to acknowledge funding sources, please see For more information on how to obtain a PMCID, please see

For more information on the CCSG, please contact Erin Bank, PhD, at